- A phase 1 clinical trial evaluated the safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults.
- The novel vaccine platform aims to induce broader responses against viral protein domains conserved among influenza subtypes.
- The trial included participants who were either H2-naive or had pre-existing responses against the immunodominant HA head domain.
- Fifty healthy participants aged 18-70 received the H2HA-Ferritin vaccine in various dosing regimens.
- The primary objective of the trial was to assess the safety and tolerability of the vaccine.
- The results of the trial are not provided in the given summary.